Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

967515

registered interest
date	04/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the answer by Lord O'Shaughnessy on 7 June (HL Deb, col 1405), what assessment they have made of the credibility of the National Institute for Health and Care Excellence (NICE) process to approve drugs for use by NHS England; and what discussions they have held with NHS England on the subject of the application of NICE standards for Ibrutinib.
tabling member printed	Baroness Prosser
uin	HL10002
answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) technology appraisal methods and processes are internationally respected and have been developed through periodic review, including extensive engagement with stakeholders, to ensure that they remain fit for purpose.</p><p>Departmental officials and I have met with NHS England to discuss the treatment criteria relating to the use of ibrutinib for the treatment of chronic lymphocytic leukaemia (CLL). NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of NICE guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>NHS England has recently completed a review of the treatment criteria related to the use of ibrutinib for the treatment of CLL which concluded that the criteria should be amended such that ibrutinib can be made available as a treatment option for those patients who have had remission durations of three years or more with their preceding line of therapy. Ibrutinib is now available for National Health Service patients in line with the amended treatment criteria.</p> answering member printed Lord O'Shaughnessy question first answered 17/09/2018 13:52:59 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	3684 label Biography information for Baroness Prosser

967805

registered interest
date	04/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of the UK leaving the EU on patient access to short-shelf life medicines.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	170342
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>The Government has made significant progress in negotiations with the European Union and remains confident the United Kingdom will leave with a good deal for both sides. This deal will include ensuring patients in the UK have access to appropriate, safe, and cost effective medicines, including short shelf-life medicines.</p><p> </p><p>However, as a responsible Government, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the EU without any deal in March 2019. Therefore on 23 August 2018, the Department wrote to a number of pharmaceutical companies that supply medicines for National Health Service patients from, or via, the EU/European Economic Area (EEA), asking them to ensure that they have a minimum of six weeks additional supply in the UK, over and above their business as usual operational buffer stocks by 29 March 2019.</p><p> </p><p>For certain medicines with short shelf lives, which cannot be reasonably stockpiled, we are specifically asking that where these products are imported to the UK from the EU/EEA via road haulage and roll-on, roll-off sea, road and rail routes, suppliers ensure in advance plans to air freight these medicines to the UK. This will ensure that UK patients have the same access to these medicines as they currently do in unlikely event of the UK leaving the EU without a deal.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/09/2018 16:26:05 answering member 4067 label Biography information for Steve Brine
tabling member	4382 label Biography information for Daniel Zeichner

967869

registered interest
date	04/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what guidance his Department received when determining the length of time medicines will need to be stockpiled in the event that the UK leaves the EU without a deal; if he will publish that guidance.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	170317
answer	answer is ministerial correction date of answer 10/09/2018 answer text <p>As we set out in the Department’s letter to the pharmaceutical industry on 23 August, in the unlikely event we leave the European Union without a deal in March 2019, based on the current cross-Government planning scenario, we will ensure the United Kingdom has an additional six weeks supply of medicines in case imports from the EU through certain routes are affected. This is the current planning assumption but will of course be subject to revision in light of future developments.</p><p> </p><p>The Government has not asked the NHS to stockpile medicines. It has asked industry to make preparations for doing so.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 170318 question first answered 10/09/2018 16:13:06 answering member 4095 label Biography information for Steve Barclay
tabling member	4244 label Biography information for Jonathan Ashworth

967870

registered interest
date	04/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the public purse of the NHS stockpiling medicines for six weeks in the event that the UK leaves the EU without a deal; and whether that cost will be borne from existing Department of Health budgets.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	170318
answer	answer is ministerial correction date of answer 10/09/2018 answer text <p>As we set out in the Department’s letter to the pharmaceutical industry on 23 August, in the unlikely event we leave the European Union without a deal in March 2019, based on the current cross-Government planning scenario, we will ensure the United Kingdom has an additional six weeks supply of medicines in case imports from the EU through certain routes are affected. This is the current planning assumption but will of course be subject to revision in light of future developments.</p><p> </p><p>The Government has not asked the NHS to stockpile medicines. It has asked industry to make preparations for doing so.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 170317 question first answered 10/09/2018 16:13:06 answering member 4095 label Biography information for Steve Barclay
tabling member	4244 label Biography information for Jonathan Ashworth